up-to-date with a click!
Update November, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications November 2018

Add on treatments

  1. Marazzi G, Campolongo G, Pelliccia F et al. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420184
  2. Garcia-Mendez RC, Almeida-Gutierrez E, Serrano-Cuevas L et al. Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction. Arch Med Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446246
  3. Knecht T, Borlongan C, Dela Pena I. Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator. Brain circulation 2018; 4:99-108. http://www.ncbi.nlm.nih.gov/pubmed/?term=30450415
  4. Zhiqiang Z, Niu X, Dong Z et al. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF). Cardiovasc Ther 2018:e12478. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390409
  5. Heeney SA, Tjugum SL, Corkish ME, Hollis IB. Safety and tolerability of high intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. Clinical transplantation 2018:e13454. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485535
  6. Zhan S, Tang M, Liu F et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane database of systematic reviews 2018; 11:Cd012502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30480766
  7. Hansen M, Kuhlman ACB, Sahl RE et al. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389229
  8. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug design, development and therapy 2018; 12:3607-3615. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464392
  9. Sampalis JS, Psaradellis E, Stutz M et al. Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly. Drugs in R&D 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448890
  10. Li T, Yao W. Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. Experimental and therapeutic medicine 2018; 16:4119-4123. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402154
  11. Wang L, Zhou B, Zhou X et al. Combined lowering effects of rosuvastatin and L. acidophilus on cholesterol levels in rat. Journal of microbiology and biotechnology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415528
  12. Bonaca MP, Gutierrez JA, Cannon C et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. The lancet. Diabetes & endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396865
  13. Wu NQ, Guo YL, Zhu CG et al. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018; 17:265. http://www.ncbi.nlm.nih.gov/pubmed/?term=30470229
  14. Magdy R, Hemdan A, Fares NV, Farouk M. Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2018; 210:203-211. http://www.ncbi.nlm.nih.gov/pubmed/?term=30453196

Adherence

  1. Ofori-Asenso R, Ilomaki J, Tacey M et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402916
  2. Guntekin U, Gumrukcuoglu HA, Yaman M et al. Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention? Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30392816

Atherosclerosis & Imaging

  1. Garcia-Mendez RC, Almeida-Gutierrez E, Serrano-Cuevas L et al. Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction. Arch Med Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446246
  2. Qvist I, Sogaard R, Lindholt JS et al. Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393062
  3. Parisi V, Petraglia L, D'Esposito V et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol 2019; 274:326-330. http://www.ncbi.nlm.nih.gov/pubmed/?term=30454723
  4. Mitchell JD, Fergestrom N, Gage BF et al. Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30409567
  5. Capoulade R, Yeang C, Chan KL et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476957
  6. Kosmas CE, Silverio D, Ovalle J et al. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient preference and adherence 2018; 12:2263-2266. http://www.ncbi.nlm.nih.gov/pubmed/?term=3046441

Atorvastatin/Rosuvastatin

  1. Liu P, Liu Y, Li P et al. Rosuvastatin- and Heparin-Loaded Poly(L-Lactide-Co-Caprolactone) Nanofibre Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30403126
  2. Su J, Fang M, Tian B et al. Atorvastatin protects cardiac progenitor cells from hypoxia-induced cell growth inhibition via MEG3/miR-22/HMGB1 pathway. Acta biochimica et biophysica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30481260
  3. Guedeney P, Baber U, Claessen B et al. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J 2018; 207:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30404046
  4. Co MLF, Agdamag AC, Co MZ et al. Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30442361
  5. Garcia-Mendez RC, Almeida-Gutierrez E, Serrano-Cuevas L et al. Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction. Arch Med Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446246
  6. Zhao J, Cheng Q, Liu Y et al. Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 109:602-609. http://www.ncbi.nlm.nih.gov/pubmed/?term=30399597
  7. Hassan SMS, Rizk A, Thomann C et al. Preconditioning with atorvastatin against renal ischemic-reperfusion injury in non-diabetic versus diabetic rats. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30412424
  8. Yuan HW, Ji RJ, Lin YJ et al. Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420288
  9. Itoh H, Komuro I, Takeuchi M et al. Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy Study. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393955
  10. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug design, development and therapy 2018; 12:3607-3615. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464392
  11. Lwin EMP, Leggett C, Ritchie U et al. Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations. Drug design, development and therapy 2018; 12:3645-3651. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464396
  12. Zhang J, Guo Y, Jin Q et al. Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury. Drug design, development and therapy 2018; 12:3685-3690. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464400
  13. Sampalis JS, Psaradellis E, Stutz M et al. Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly. Drugs in R&D 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448890
  14. Hassan R, Tammam SN, El Safy S et al. Prevention of Hepatic Stellate Cell Activation using JQ1- and Atorvastatin-Loaded Chitosan Nanoparticles as a Promising Approach in Therapy of Liver Fibrosis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30471341
  15. Li T, Yao W. Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. Experimental and therapeutic medicine 2018; 16:4119-4123. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402154
  16. Baik SY, Kim H, Yang SJ et al. Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea. Frontiers of medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483915
  17. Zhang L, Zhang S, Yu Y et al. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Herz 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483816
  18. Guan S, Zhang Y, Wang B, Li W. Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD. Int Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464115
  19. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30478491
  20. Wang L, Zhou B, Zhou X et al. Combined lowering effects of rosuvastatin and L. acidophilus on cholesterol levels in rat. Journal of microbiology and biotechnology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415528
  21. El-Zailik A, Cheung LK, Wang Y et al. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. Journal of pharmaceutical and biomedical analysis 2018; 164:258-267. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396053
  22. Wu NQ, Guo YL, Zhu CG et al. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018; 17:265. http://www.ncbi.nlm.nih.gov/pubmed/?term=30470229
  23. Ong KL, Hui N, Januszewski AS et al. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30452928
  24. Geng J, Xu H, Yu X et al. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483737
  25. Ahmed IS, El-Hosary R, Hassan M et al. Correction to "Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution". Molecular pharmaceutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30484318
  26. Polster SP, Stadnik A, Akers AL et al. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476251
  27. Liping Z, Xiufang L, Tao Y et al. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci 2018; 31:2203-2208. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463813
  28. Soko ND, Masimirembwa C, Dandara C. Rosuvastatin pharmacogenetics in African populations. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30398065
  29. Magdy R, Hemdan A, Fares NV, Farouk M. Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2018; 210:203-211. http://www.ncbi.nlm.nih.gov/pubmed/?term=30453196
  30. Song ZC, Chen L, Zhang D et al. [Rosuvastatin protects acute myocardial infarction rats through autophagy regulation via AMPK signaling]. Zhonghua yi xue za zhi 2018; 98:3536-3541. http://www.ncbi.nlm.nih.gov/pubmed/?term=30481906

Basic science

  1. Liu P, Liu Y, Li P et al. Rosuvastatin- and Heparin-Loaded Poly(L-Lactide-Co-Caprolactone) Nanofibre Aneurysm Stent Promotes Endothelialization via Vascular Endothelial Growth Factor Type A Modulation. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30403126
  2. Itoh H, Matsui M, Miyamura Y et al. Biosynthesis of Novel Statins by Combining Heterologous Genes from Xylaria and Aspergillus. ACS synthetic biology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30403849
  3. Su J, Fang M, Tian B et al. Atorvastatin protects cardiac progenitor cells from hypoxia-induced cell growth inhibition via MEG3/miR-22/HMGB1 pathway. Acta biochimica et biophysica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30481260
  4. Yorulmaz H, Ozkok E, Demir G et al. Pretreatment of simvastatin on liver trace element levels during endotoxemia. Archives of physiology and biochemistry 2018:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=30450988
  5. Dai M, Chen Y, Mei X. Pravastatin sodium attenuated TREM-1-mediated inflammation in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30473214
  6. Zhao J, Cheng Q, Liu Y et al. Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 109:602-609. http://www.ncbi.nlm.nih.gov/pubmed/?term=30399597
  7. Fawzy Fahim V, Wadie W, Shafik AN, Ishak Attallah M. Role of simvastatin and insulin in memory protection in a rat model of diabetes mellitus and dementia. Brain research bulletin 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30395886
  8. Matusewicz L, Podkalicka J, Sikorski AF. Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30388834
  9. Huang Y, Zhang J, Shao H et al. miR-33a Mediates the Anti-Tumor Effect of Lovastatin in Osteosarcoma by Targeting CYR61. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 51:938-948. http://www.ncbi.nlm.nih.gov/pubmed/?term=30466075
  10. Soliman NA, Keshk WA, Rizk FH, Ibrahim MAA. The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats. Chemico-biological interactions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30408459
  11. Halandras PM. Vascular Surgery and Geriatric Patients. Clinics in geriatric medicine 2019; 35:93-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390986
  12. Li J, Yang M, Xu WR. Enhanced oral bioavailability of fluvastatin by using nanosuspensions containing cyclodextrin. Drug design, development and therapy 2018; 12:3491-3499. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425452
  13. Zhang Z, Zhang HY, Zhang Y, Li H. Inactivation of the Ras/MAPK/PPARgamma signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30460485
  14. Hassan R, Tammam SN, El Safy S et al. Prevention of Hepatic Stellate Cell Activation using JQ1- and Atorvastatin-Loaded Chitosan Nanoparticles as a Promising Approach in Therapy of Liver Fibrosis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30471341
  15. Domokos D, Ducza E, Gaspar R. RhoA and Rho-kinase inhibitors modulate cervical resistance: the possible role of RhoA/Rho-kinase signalling pathway in cervical ripening and contractility. Eur J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30445018
  16. Chen X, Zhuang X, Peng Z et al. Intensive Statin Therapy for Acute Ischemic Stroke to Reduce the Number of Microemboli: A Preliminary, Randomized Controlled Study. European neurology 2018; 80:163-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485853
  17. Li T, Yao W. Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. Experimental and therapeutic medicine 2018; 16:4119-4123. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402154
  18. Jang H, Lee J, Park S et al. Pravastatin Attenuates Acute Radiation-Induced Enteropathy and Improves Epithelial Cell Function. Frontiers in pharmacology 2018; 9:1215. http://www.ncbi.nlm.nih.gov/pubmed/?term=30459609
  19. Qu L, Li D, Gao X et al. Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE(-/-) Mice by Downregulating PCSK9. Frontiers in pharmacology 2018; 9:1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443213
  20. Hajihasani Biouki M, Mobedi H, Karkhaneh A, Daliri Joupari M. Development of a simvastatin loaded injectable porous scaffold in situ formed by phase inversion method for bone tissue regeneration. The International journal of artificial organs 2018:391398818806161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30482084
  21. Bocate KP, Reis GF, de Souza PC et al. Antifungal activity of silver nanoparticles and simvastatin against toxigenic species of Aspergillus. International journal of food microbiology 2018; 291:79-86. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476736
  22. Su F, Shi M, Zhang J et al. Simvastatin Protects Heart from Pressure Overload Injury by Inhibiting Excessive Autophagy. International journal of medical sciences 2018; 15:1508-1516. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443172
  23. Gulzar M, Ali S, Khan FI et al. Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: A comparative docking and MD simulation studies. Journal of biomolecular structure & dynamics 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30488773
  24. Atef MM, Hafez YM, Alshenawy HA, Emam MN. Ameliorative effects of autophagy inducer, simvastatin on alcohol-induced liver disease in a rat model. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30417426
  25. Bukiya AN, Blank PS, Rosenhouse-Dantsker A. Cholesterol intake and statin use regulate neuronal G protein-gated inwardly rectifying potassium channels. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420402
  26. Wang L, Zhou B, Zhou X et al. Combined lowering effects of rosuvastatin and L. acidophilus on cholesterol levels in rat. Journal of microbiology and biotechnology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415528
  27. Matsushita M, Kawaguchi M. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy. Journal of oncology 2018; 2018:8653489. http://www.ncbi.nlm.nih.gov/pubmed/?term=30498512
  28. El-Zailik A, Cheung LK, Wang Y et al. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. Journal of pharmaceutical and biomedical analysis 2018; 164:258-267. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396053
  29. Wang Y, Wang X, Yang W et al. Effect of Simvastatin on the Intestinal Rho/ROCK Signaling Pathway in Rats With Sepsis. J Surg Res 2018; 232:531-538. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463769
  30. Kim AR, Kim JH, Kim A et al. Simvastatin attenuates tibial bone loss in rats with type 1 diabetes and periodontitis. Journal of translational medicine 2018; 16:306. http://www.ncbi.nlm.nih.gov/pubmed/?term=30413166
  31. Capoulade R, Yeang C, Chan KL et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476957
  32. Dong L, Xue L, Zhang C et al. HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483734
  33. Geng J, Xu H, Yu X et al. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483737
  34. Ahmed IS, El-Hosary R, Hassan M et al. Correction to "Efficacy and Safety Profiles of Oral Atorvastatin-Loaded Nanoparticles: Effect of Size Modulation on Biodistribution". Molecular pharmaceutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30484318
  35. Khoshnejad M, Patel A, Wojtak K et al. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30449662
  36. Mehibel M, Ortiz-Martinez F, Voelxen N et al. Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. Scientific reports 2018; 8:16804. http://www.ncbi.nlm.nih.gov/pubmed/?term=30429503
  37. Pontremoli M, Brioschi M, Baetta R et al. Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells. Scientific reports 2018; 8:16671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420710
  38. Magdy R, Hemdan A, Fares NV, Farouk M. Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2018; 210:203-211. http://www.ncbi.nlm.nih.gov/pubmed/?term=30453196
  39. Yin E, Hara M, Uchiyama M, Niimi M. Graft Protective Effect of HMG-CoA Reductase Inhibitor Pravastatin in Murine Cardiac Allograft Transplantation. Transplantation proceedings 2018; 50:2804-2806. http://www.ncbi.nlm.nih.gov/pubmed/?term=30401401
  40. Song ZC, Chen L, Zhang D et al. [Rosuvastatin protects acute myocardial infarction rats through autophagy regulation via AMPK signaling]. Zhonghua yi xue za zhi 2018; 98:3536-3541. http://www.ncbi.nlm.nih.gov/pubmed/?term=3048190

Cancer

  1. Cakir SS, Ozcan L, Polat EC et al. Statins are effective in the treatment of benign prostatic hyperplasia with metabolic syndrome. The aging male : the official journal of the International Society for the Study of the Aging Male 2018:1-6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463466
  2. Beckwitt CH, Clark AM, Ma B et al. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer 2018; 119:1094-1105. http://www.ncbi.nlm.nih.gov/pubmed/?term=30401978
  3. Beckwitt CH, Brufsky A, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast cancer research : BCR 2018; 20:144. http://www.ncbi.nlm.nih.gov/pubmed/?term=30458856
  4. Kim Y, Kim TW, Han SW et al. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer research and treatment : official journal of Korean Cancer Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30477287
  5. Matusewicz L, Podkalicka J, Sikorski AF. Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30388834
  6. Huang Y, Zhang J, Shao H et al. miR-33a Mediates the Anti-Tumor Effect of Lovastatin in Osteosarcoma by Targeting CYR61. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 51:938-948. http://www.ncbi.nlm.nih.gov/pubmed/?term=30466075
  7. Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30465184
  8. Kobayashi Y, Banno K, Kunitomi H et al. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30418231
  9. Liu Z, Alsaggaf R, McGlynn KA et al. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448774
  10. Shah SC, Glass J, Giustino G et al. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in patients with Inflammatory Bowel Disease. Gut Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400722
  11. Gulzar M, Ali S, Khan FI et al. Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: A comparative docking and MD simulation studies. Journal of biomolecular structure & dynamics 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30488773
  12. Roy S, Vallepu S, Barrios C, Hunter K. Comparison of Comorbid Conditions Between Cancer Survivors and Age-Matched Patients Without Cancer. Journal of clinical medicine research 2018; 10:911-919. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425764
  13. Matsushita M, Kawaguchi M. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy. Journal of oncology 2018; 2018:8653489. http://www.ncbi.nlm.nih.gov/pubmed/?term=30498512
  14. Li J, Liu R, Sun Z et al. The association between statin use and endometrial cancer survival outcome: A meta-analysis. Medicine (Baltimore) 2018; 97:e13264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461633
  15. Dong L, Xue L, Zhang C et al. HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483734
  16. Spence AD, Busby J, Hughes CM et al. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30456916
  17. Mehibel M, Ortiz-Martinez F, Voelxen N et al. Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. Scientific reports 2018; 8:16804. http://www.ncbi.nlm.nih.gov/pubmed/?term=30429503 

Cost-effectiveness

  1. Li T, Wan X, Ma J, Wu B. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Adv Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390239
  2. Colantonio LD, Deng L, Chen L et al. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446883
  3. Yuan HW, Ji RJ, Lin YJ et al. Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420288
  4. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30478491

CVD

  1. Garcia-Mendez RC, Almeida-Gutierrez E, Serrano-Cuevas L et al. Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial Infarction. Arch Med Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446246
  2. Humphries SE, Cooper JA, Capps N et al. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30458964
  3. Laleman N, Henrard S, van den Akker M et al. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord 2018; 18:209. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400778
  4. Kim YH, Her AY, Jeong MH et al. Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30474346
  5. Marume K, Takashio S, Nagai T et al. Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease- Report From the JASPER Study. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30416189
  6. Zhan S, Tang M, Liu F et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane database of systematic reviews 2018; 11:Cd012502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30480766
  7. Siskos D, Tziomalos K. The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423861
  8. Guan S, Zhang Y, Wang B, Li W. Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD. Int Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464115
  9. Mitchell JD, Fergestrom N, Gage BF et al. Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30409567
  10. Bonaca MP, Gutierrez JA, Cannon C et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. The lancet. Diabetes & endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396865
  11. Kasama S, Toyama T, Suzuki S et al. Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure. Nuclear medicine communications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461696

Endothelium/inflammation

  1. Barale C, Frascaroli C, Senkeev R et al. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed research international 2018; 2018:6508709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402489
  2. Hansen M, Kuhlman ACB, Sahl RE et al. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389229
  3. Francesconi LP, Victorino AT, Salah IA et al. Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. International clinical psychopharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461427
  4. Parisi V, Petraglia L, D'Esposito V et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol 2019; 274:326-330. http://www.ncbi.nlm.nih.gov/pubmed/?term=30454723
  5. Wu NQ, Guo YL, Zhu CG et al. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018; 17:265. http://www.ncbi.nlm.nih.gov/pubmed/?term=30470229
  6. Pontremoli M, Brioschi M, Baetta R et al. Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells. Scientific reports 2018; 8:16671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420710

Ethnicity

  1. Kim YH, Her AY, Jeong MH et al. Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30474346
  2. Superko HR, Williams PT, Dansinger M, Schaefer E. Trends in LDL-cholesterol Blood Values between 2012 and 2017 suggest Sluggish Adoption of the recent 2013 Treatment Guidelines. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30444024
  3. Tabesh M, Magliano DJ, Tanamas SK et al. Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015. Diabetic medicine : a journal of the British Diabetic Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402961
  4. Asberg S, Farahmand B, Henriksson KM, Appelros P. Statins as secondary preventives in patients with intracerebral hemorrhage. Int J Stroke 2018:1747493018816476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30484749
  5. Azhar W, Buczkowski B, Smith C, Onambele-Pearson G. Impact of Circulating Triglycerides Concentration on Atherosclerotic Disease Status in Middle-Aged Saudi Arabian Dwellers. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400262
  6. Soko ND, Masimirembwa C, Dandara C. Rosuvastatin pharmacogenetics in African populations. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30398065

FH

  1. Humphries SE, Cooper JA, Capps N et al. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30458964
  2. Superko HR, Williams PT, Dansinger M, Schaefer E. Trends in LDL-cholesterol Blood Values between 2012 and 2017 suggest Sluggish Adoption of the recent 2013 Treatment Guidelines. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30444024
  3. Ravnskov U, de Lorgeril M, Kendrick M, Diamond DM. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Medical hypotheses 2018; 121:60-63. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396495

Generics

  1. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30478491

Genetics

  1. Soko ND, Masimirembwa C, Dandara C. Rosuvastatin pharmacogenetics in African populations. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30398065

Guidelines

  1. Bavishi A, Howard T, Kim JP et al. Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30497653
  2. Superko HR, Williams PT, Dansinger M, Schaefer E. Trends in LDL-cholesterol Blood Values between 2012 and 2017 suggest Sluggish Adoption of the recent 2013 Treatment Guidelines. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30444024
  3. Guntekin U, Gumrukcuoglu HA, Yaman M et al. Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention? Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30392816
  4. Rigobon AV, Kalia S, Nichols J et al. Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010-2015. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389671
  5. Pennells L, Kaptoge S, Wood A et al. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. Eur Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476079
  6. Lloyd-Jones DM, Braun LT, Ndumele CE et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423392
  7. Wilson PWF, Polonsky TS, Miedema MD et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423394
  8. Klug E, Raal FJ, Marais AD et al. South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2018; 108:973-1000. http://www.ncbi.nlm.nih.gov/pubmed/?term=30421699

LDL- related parameters

  1. Itoh H, Komuro I, Takeuchi M et al. Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy Study. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393955
  2. Zhang L, Zhang S, Yu Y et al. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Herz 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483816
  3. Capoulade R, Yeang C, Chan KL et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476957

Lifestyle

  1. Marazzi G, Campolongo G, Pelliccia F et al. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420184
  2. Qu L, Li D, Gao X et al. Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE(-/-) Mice by Downregulating PCSK9. Frontiers in pharmacology 2018; 9:1170. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443213
  3. Acimovic MG, Milic NB. Perspectives of the Apiaceae Hepatoprotective Effects - A Review. Natural product communications 2017; 12:309-317. http://www.ncbi.nlm.nih.gov/pubmed/?term=30428236

Meta-analyses

  1. Pertzov B, Eliakim-Raz N, Atamna H et al. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30472427
  2. Zhan S, Tang M, Liu F et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. The Cochrane database of systematic reviews 2018; 11:Cd012502. http://www.ncbi.nlm.nih.gov/pubmed/?term=30480766
  3. Zhang J, Guo Y, Jin Q et al. Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury. Drug design, development and therapy 2018; 12:3685-3690. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464400
  4. Qu H, Meng YY, Chai H et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. European journal of medical research 2018; 23:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30414615
  5. Zhang L, Zhang S, Yu Y et al. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. Herz 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483816
  6. Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients. Int J Endocrinol 2018; 2018:8380192. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425742

Metabolic Syndrome - Diabetes

  1. Fawzy Fahim V, Wadie W, Shafik AN, Ishak Attallah M. Role of simvastatin and insulin in memory protection in a rat model of diabetes mellitus and dementia. Brain research bulletin 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30395886
  2. Oshakbayev K, Bimbetov B, Manekenova K et al. Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. Current medical research and opinion 2018:1-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30431378
  3. Tabesh M, Magliano DJ, Tanamas SK et al. Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015. Diabetic medicine : a journal of the British Diabetic Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402961
  4. Rigobon AV, Kalia S, Nichols J et al. Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010-2015. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389671
  5. Itoh H, Komuro I, Takeuchi M et al. Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy Study. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393955
  6. Zhang Z, Zhang HY, Zhang Y, Li H. Inactivation of the Ras/MAPK/PPARgamma signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30460485
  7. Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients. Int J Endocrinol 2018; 2018:8380192. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425742
  8. Moczygemba LR, Bhathena S, DiPiro CV, Snead R. Pharmacist documentation of gaps in care identified during diabetes coaching. Journal of the American Pharmacists Association : JAPhA 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446422

New Treatments

  1. Koskinas KC, Windecker S, Buhayer A et al. Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30421481
  2. Szarek M, White HD, Schwartz GG et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30428396
  3. Khoshnejad M, Patel A, Wojtak K et al. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30449662
  4. Bhatt DL, Steg PG, Miller M et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415628
  5. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420622
  6. Kosmas CE, Silverio D, Ovalle J et al. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient preference and adherence 2018; 12:2263-2266. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464416

Other

  1. Allende C, Gusmano MK, Weisz D. Disparities in Statin Use in New York City: Implications for Health Reform. Journal of racial and ethnic health disparities 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30456578 

PAD and statins

  1. Zhang Z, Zhang HY, Zhang Y, Li H. Inactivation of the Ras/MAPK/PPARgamma signaling axis alleviates diabetic mellitus-induced erectile dysfunction through suppression of corpus cavernosal endothelial cell apoptosis by inhibiting HMGCS2 expression. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30460485
  2. Qvist I, Sogaard R, Lindholt JS et al. Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393062
  3. Bonaca MP, Gutierrez JA, Cannon C et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. The lancet. Diabetes & endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396865
  4. Liping Z, Xiufang L, Tao Y et al. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci 2018; 31:2203-2208. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463813

Pleiotropic effects of statins

  1. Su J, Fang M, Tian B et al. Atorvastatin protects cardiac progenitor cells from hypoxia-induced cell growth inhibition via MEG3/miR-22/HMGB1 pathway. Acta biochimica et biophysica Sinica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30481260
  2. Yorulmaz H, Ozkok E, Demir G et al. Pretreatment of simvastatin on liver trace element levels during endotoxemia. Archives of physiology and biochemistry 2018:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=30450988
  3. Dai M, Chen Y, Mei X. Pravastatin sodium attenuated TREM-1-mediated inflammation in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30473214
  4. Zhao J, Cheng Q, Liu Y et al. Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 109:602-609. http://www.ncbi.nlm.nih.gov/pubmed/?term=30399597
  5. Barale C, Frascaroli C, Senkeev R et al. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed research international 2018; 2018:6508709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402489
  6. Beckwitt CH, Clark AM, Ma B et al. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer 2018; 119:1094-1105. http://www.ncbi.nlm.nih.gov/pubmed/?term=30401978
  7. Fawzy Fahim V, Wadie W, Shafik AN, Ishak Attallah M. Role of simvastatin and insulin in memory protection in a rat model of diabetes mellitus and dementia. Brain research bulletin 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30395886
  8. Hassan SMS, Rizk A, Thomann C et al. Preconditioning with atorvastatin against renal ischemic-reperfusion injury in non-diabetic versus diabetic rats. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30412424
  9. Matusewicz L, Podkalicka J, Sikorski AF. Immunoliposomes with Simvastatin as a Potential Therapeutic in Treatment of Breast Cancer Cells Overexpressing HER2-An In Vitro Study. Cancers 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30388834
  10. Zhiqiang Z, Niu X, Dong Z et al. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF). Cardiovasc Ther 2018:e12478. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390409
  11. Soliman NA, Keshk WA, Rizk FH, Ibrahim MAA. The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats. Chemico-biological interactions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30408459
  12. Stokkeland K, Hoijer J, Bottai M et al. Statin Use is Associated with Improved Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448601
  13. Halandras PM. Vascular Surgery and Geriatric Patients. Clinics in geriatric medicine 2019; 35:93-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390986
  14. Pertzov B, Eliakim-Raz N, Atamna H et al. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults - a systematic review and meta-analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30472427
  15. Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30465184
  16. Mudyanadzo TA. Endothelial Progenitor Cells and Cardiovascular Correlates. Cureus 2018; 10:e3342. http://www.ncbi.nlm.nih.gov/pubmed/?term=30473975
  17. Oshakbayev K, Bimbetov B, Manekenova K et al. Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. Current medical research and opinion 2018:1-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30431378
  18. Amariei DE, Reed RM. The role of statins in chronic obstructive pulmonary disease: is cardiovascular disease the common denominator? Statins, chronic obstructive pulmonary disease, and inflammation: is cardiovascular disease closing the loop? Current opinion in pulmonary medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30418244
  19. Hansen M, Kuhlman ACB, Sahl RE et al. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389229
  20. Zhang J, Guo Y, Jin Q et al. Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury. Drug design, development and therapy 2018; 12:3685-3690. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464400
  21. Hassan R, Tammam SN, El Safy S et al. Prevention of Hepatic Stellate Cell Activation using JQ1- and Atorvastatin-Loaded Chitosan Nanoparticles as a Promising Approach in Therapy of Liver Fibrosis. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30471341
  22. Domokos D, Ducza E, Gaspar R. RhoA and Rho-kinase inhibitors modulate cervical resistance: the possible role of RhoA/Rho-kinase signalling pathway in cervical ripening and contractility. Eur J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30445018
  23. Jang H, Lee J, Park S et al. Pravastatin Attenuates Acute Radiation-Induced Enteropathy and Improves Epithelial Cell Function. Frontiers in pharmacology 2018; 9:1215. http://www.ncbi.nlm.nih.gov/pubmed/?term=30459609
  24. Liu Z, Alsaggaf R, McGlynn KA et al. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448774
  25. Shah SC, Glass J, Giustino G et al. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in patients with Inflammatory Bowel Disease. Gut Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400722
  26. Hajihasani Biouki M, Mobedi H, Karkhaneh A, Daliri Joupari M. Development of a simvastatin loaded injectable porous scaffold in situ formed by phase inversion method for bone tissue regeneration. The International journal of artificial organs 2018:391398818806161. http://www.ncbi.nlm.nih.gov/pubmed/?term=30482084
  27. Bocate KP, Reis GF, de Souza PC et al. Antifungal activity of silver nanoparticles and simvastatin against toxigenic species of Aspergillus. International journal of food microbiology 2018; 291:79-86. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476736
  28. Gulzar M, Ali S, Khan FI et al. Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: A comparative docking and MD simulation studies. Journal of biomolecular structure & dynamics 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30488773
  29. Atef MM, Hafez YM, Alshenawy HA, Emam MN. Ameliorative effects of autophagy inducer, simvastatin on alcohol-induced liver disease in a rat model. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30417426
  30. Larsson BAM, Sundh D, Mellstrom D et al. Association between cortical bone microstructure and statin use in older women. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423123
  31. Matsushita M, Kawaguchi M. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy. Journal of oncology 2018; 2018:8653489. http://www.ncbi.nlm.nih.gov/pubmed/?term=30498512
  32. Wang Y, Wang X, Yang W et al. Effect of Simvastatin on the Intestinal Rho/ROCK Signaling Pathway in Rats With Sepsis. J Surg Res 2018; 232:531-538. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463769
  33. Kim AR, Kim JH, Kim A et al. Simvastatin attenuates tibial bone loss in rats with type 1 diabetes and periodontitis. Journal of translational medicine 2018; 16:306. http://www.ncbi.nlm.nih.gov/pubmed/?term=30413166
  34. Dong L, Xue L, Zhang C et al. HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483734
  35. Geng J, Xu H, Yu X et al. Rosuvastatin protects against oxidized lowdensity lipoproteininduced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483737
  36. Polster SP, Stadnik A, Akers AL et al. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476251
  37. Kasama S, Toyama T, Suzuki S et al. Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure. Nuclear medicine communications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461696
  38. Spence AD, Busby J, Hughes CM et al. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30456916
  39. Yucel H, Yucel A, Arbag H et al. Effect of Statins on Hearing Function and Subjective Tinnitus in Hyperlipidemic Patients. Romanian journal of internal medicine = Revue roumaine de medecine interne 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30447148
  40. Chia PY, Htun HL, Ling WP et al. Hyperlipidemia, statin use and dengue severity. Scientific reports 2018; 8:17147. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464247
  41. Hu PJ, Wu MY, Lin TC et al. Effect of Statins on Renal Function in Chronic Kidney Disease Patients. Scientific reports 2018; 8:16276. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390007
  42. Song ZC, Chen L, Zhang D et al. [Rosuvastatin protects acute myocardial infarction rats through autophagy regulation via AMPK signaling]. Zhonghua yi xue za zhi 2018; 98:3536-3541. http://www.ncbi.nlm.nih.gov/pubmed/?term=30481906

Primary Prevention

  1. Li T, Wan X, Ma J, Wu B. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Adv Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390239
  2. Bavishi A, Howard T, Kim JP et al. Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30497653
  3. Thanassoulis G, Sniderman AD, Pencina MJ. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30422172

Registry data

  1. Bavishi A, Howard T, Kim JP et al. Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30497653
  2. Humphries SE, Cooper JA, Capps N et al. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30458964
  3. Laleman N, Henrard S, van den Akker M et al. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovasc Disord 2018; 18:209. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400778
  4. Ofori-Asenso R, Ilomaki J, Tacey M et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402916
  5. Colantonio LD, Deng L, Chen L et al. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446883
  6. Stokkeland K, Hoijer J, Bottai M et al. Statin Use is Associated with Improved Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448601
  7. Navaneethan SD, Akeroyd JM, Ramsey D et al. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30498000
  8. Guntekin U, Gumrukcuoglu HA, Yaman M et al. Compliance With Dyslipidemia Guidelines in Daily Practice: How Effective Is Cardiovascular Risk Prevention? Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30392816
  9. Yuan HW, Ji RJ, Lin YJ et al. Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420288
  10. Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30465184
  11. Rigobon AV, Kalia S, Nichols J et al. Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010-2015. Diabetes Care 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389671
  12. Bykov K, Mittleman MA, Glynn RJ et al. The case-crossover design for drug-drug interactions: considerations for implementation. Epidemiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30433922
  13. Essers D, Schaublin M, Kullak-Ublick GA, Weiler S. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30430215
  14. Liu Z, Alsaggaf R, McGlynn KA et al. Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448774
  15. Shah SC, Glass J, Giustino G et al. Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in patients with Inflammatory Bowel Disease. Gut Liver 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400722
  16. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30478491
  17. Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients. Int J Endocrinol 2018; 2018:8380192. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425742
  18. Mitchell JD, Fergestrom N, Gage BF et al. Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30409567
  19. Moczygemba LR, Bhathena S, DiPiro CV, Snead R. Pharmacist documentation of gaps in care identified during diabetes coaching. Journal of the American Pharmacists Association : JAPhA 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446422
  20. Larsson BAM, Sundh D, Mellstrom D et al. Association between cortical bone microstructure and statin use in older women. J Clin Endocrinol Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423123
  21. Ofori-Asenso R, Ilomaki J, Tacey M et al. Predictors of statin use among older adults: A nationwide cross-sectional study. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446321
  22. Allende C, Gusmano MK, Weisz D. Disparities in Statin Use in New York City: Implications for Health Reform. Journal of racial and ethnic health disparities 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30456578
  23. Huang L, Wang L, Yang Y et al. Coexistence of anti-HMGCR and anti-MDA5 identified by an unlabeled immunoprecipitation assay in a chinese patient cohort with myositis. Medicine (Baltimore) 2018; 97:e13236. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461626
  24. Li J, Liu R, Sun Z et al. The association between statin use and endometrial cancer survival outcome: A meta-analysis. Medicine (Baltimore) 2018; 97:e13264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461633
  25. Azhar W, Buczkowski B, Smith C, Onambele-Pearson G. Impact of Circulating Triglycerides Concentration on Atherosclerotic Disease Status in Middle-Aged Saudi Arabian Dwellers. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400262
  26. Spence AD, Busby J, Hughes CM et al. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30456916
  27. Akimoto H, Negishi A, Oshima S et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect 2018; 6:e00439. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443347
  28. Chia PY, Htun HL, Ling WP et al. Hyperlipidemia, statin use and dengue severity. Scientific reports 2018; 8:17147. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464247
  29. Hu PJ, Wu MY, Lin TC et al. Effect of Statins on Renal Function in Chronic Kidney Disease Patients. Scientific reports 2018; 8:16276. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390007
  30. Guo WC, Cui M, Wang X et al. [Correlation between serum CD147 and carotid intraplaque hemorrhage]. Zhonghua yi xue za zhi 2018; 98:3437-3441. http://www.ncbi.nlm.nih.gov/pubmed/?term=3044014 

Renal Disease

  1. Co MLF, Agdamag AC, Co MZ et al. Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30442361
  2. Zhao J, Cheng Q, Liu Y et al. Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 109:602-609. http://www.ncbi.nlm.nih.gov/pubmed/?term=30399597
  3. Hassan SMS, Rizk A, Thomann C et al. Preconditioning with atorvastatin against renal ischemic-reperfusion injury in non-diabetic versus diabetic rats. Canadian journal of physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30412424
  4. Navaneethan SD, Akeroyd JM, Ramsey D et al. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30498000
  5. Aziz F, Garg N, Parajuli S et al. Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical transplantation 2018:e13452. http://www.ncbi.nlm.nih.gov/pubmed/?term=30466167
  6. Baik SY, Kim H, Yang SJ et al. Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea. Frontiers of medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483915

Reviews

  1. Barkas F, Elisaf M, Rizos EC, Liberopoulos E. Bridging the treatment gap in patients at 'extreme' cardiovascular risk: Evidence from a lipid clinic. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30471952
  2. Beckwitt CH, Brufsky A, Oltvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast cancer research : BCR 2018; 20:144. http://www.ncbi.nlm.nih.gov/pubmed/?term=30458856
  3. Aziz F, Garg N, Parajuli S et al. Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. Clinical transplantation 2018:e13452. http://www.ncbi.nlm.nih.gov/pubmed/?term=30466167
  4. Mudyanadzo TA. Endothelial Progenitor Cells and Cardiovascular Correlates. Cureus 2018; 10:e3342. http://www.ncbi.nlm.nih.gov/pubmed/?term=30473975
  5. Amariei DE, Reed RM. The role of statins in chronic obstructive pulmonary disease: is cardiovascular disease the common denominator? Statins, chronic obstructive pulmonary disease, and inflammation: is cardiovascular disease closing the loop? Current opinion in pulmonary medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30418244
  6. Siskos D, Tziomalos K. The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=30423861
  7. Pennells L, Kaptoge S, Wood A et al. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. Eur Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476079
  8. Kobayashi Y, Banno K, Kunitomi H et al. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30418231
  9. Chan P, Shao L, Tomlinson B et al. An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother 2018:1-11. http://www.ncbi.nlm.nih.gov/pubmed/?term=30482061
  10. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420622
  11. Akimoto H, Negishi A, Oshima S et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect 2018; 6:e00439. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443347
  12. Sizar O, Talati R. Ezetimibe. In: StatPearls. Treasure Island (FL): StatPearls PublishingStatPearls Publishing LLC.; 2018.
  13. Talreja O, Cassagnol M. Simvastatin. In: StatPearls. Treasure Island (FL): StatPearls PublishingStatPearls Publishing LLC.; 2018.

Safety and side effects

  1. Abdilla Y, Chircop C, Vella N. Anti-HMGCR antibody-associated necrotising myopathy and its association with statin use. BMJ case reports 2018; 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420560
  2. Colantonio LD, Deng L, Chen L et al. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446883
  3. Heeney SA, Tjugum SL, Corkish ME, Hollis IB. Safety and tolerability of high intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. Clinical transplantation 2018:e13454. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485535
  4. Hansen M, Kuhlman ACB, Sahl RE et al. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389229
  5. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects. Drug design, development and therapy 2018; 12:3607-3615. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464392
  6. Lwin EMP, Leggett C, Ritchie U et al. Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations. Drug design, development and therapy 2018; 12:3645-3651. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464396
  7. Kunwar S, Parekh JD, Chilukuri RS, Andukuri VA. Necrotizing Autoimmune myopathy: A case report on statin induced rhabdomyolysis requiring immunosuppressive therapy. Drug discoveries & therapeutics 2018; 12:315-317. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464165
  8. Bykov K, Mittleman MA, Glynn RJ et al. The case-crossover design for drug-drug interactions: considerations for implementation. Epidemiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30433922
  9. Essers D, Schaublin M, Kullak-Ublick GA, Weiler S. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30430215
  10. Qu H, Meng YY, Chai H et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. European journal of medical research 2018; 23:57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30414615
  11. Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients. Int J Endocrinol 2018; 2018:8380192. http://www.ncbi.nlm.nih.gov/pubmed/?term=30425742
  12. Panich J, Gooden A, Shirazi FM, Malone DC. Warnings for drug-drug interactions in consumer medication information provided by community pharmacies. Journal of the American Pharmacists Association : JAPhA 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30416068
  13. O'Donnell TFX, Boitano LT, Deery SE et al. Factors associated with postoperative renal dysfunction and the subsequent impact on survival after open juxtarenal abdominal aortic aneurysm repair. Journal of vascular surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30477939
  14. Huang L, Wang L, Yang Y et al. Coexistence of anti-HMGCR and anti-MDA5 identified by an unlabeled immunoprecipitation assay in a chinese patient cohort with myositis. Medicine (Baltimore) 2018; 97:e13236. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461626
  15. Akimoto H, Negishi A, Oshima S et al. Onset timing of statin-induced musculoskeletal adverse events and concomitant drug-associated shift in onset timing of MAEs. Pharmacol Res Perspect 2018; 6:e00439. http://www.ncbi.nlm.nih.gov/pubmed/?term=30443347

Stroke and CNS

  1. Knecht T, Borlongan C, Dela Pena I. Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator. Brain circulation 2018; 4:99-108. http://www.ncbi.nlm.nih.gov/pubmed/?term=30450415
  2. Yuan HW, Ji RJ, Lin YJ et al. Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Clinical therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420288
  3. Chen X, Zhuang X, Peng Z et al. Intensive Statin Therapy for Acute Ischemic Stroke to Reduce the Number of Microemboli: A Preliminary, Randomized Controlled Study. European neurology 2018; 80:163-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485853
  4. Matz O, Arndt A, Litmathe J et al. [Risk factors for hypertensive and cerebral amyloid angiopathy associated intracerebral hemorrhage: a retrospective comparison]. Fortschritte der Neurologie-Psychiatrie 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30419583
  5. Francesconi LP, Victorino AT, Salah IA et al. Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. International clinical psychopharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461427
  6. Asberg S, Farahmand B, Henriksson KM, Appelros P. Statins as secondary preventives in patients with intracerebral hemorrhage. Int J Stroke 2018:1747493018816476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30484749
  7. Tiwari V, Nagar M, Behera P, Santoshi JA. Letter to the Editor on "The Role of Perioperative Statin Use in the Prevention of Delirium After Total Knee Replacement Under Spinal Anesthesia". The Journal of arthroplasty 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30442466
  8. Bonaca MP, Gutierrez JA, Cannon C et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. The lancet. Diabetes & endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396865
  9. Guo WC, Cui M, Wang X et al. [Correlation between serum CD147 and carotid intraplaque hemorrhage]. Zhonghua yi xue za zhi 2018; 98:3437-3441. http://www.ncbi.nlm.nih.gov/pubmed/?term=30440140

Triglycerides/HDL

  1. Azhar W, Buczkowski B, Smith C, Onambele-Pearson G. Impact of Circulating Triglycerides Concentration on Atherosclerotic Disease Status in Middle-Aged Saudi Arabian Dwellers. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30400262

Trials

  1. Guedeney P, Baber U, Claessen B et al. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J 2018; 207:10-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=30404046
  2. Co MLF, Agdamag AC, Co MZ et al. Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30442361
  3. Marazzi G, Campolongo G, Pelliccia F et al. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420184
  4. Barale C, Frascaroli C, Senkeev R et al. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. BioMed research international 2018; 2018:6508709. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402489
  5. Kim Y, Kim TW, Han SW et al. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer research and treatment : official journal of Korean Cancer Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30477287
  6. Zhiqiang Z, Niu X, Dong Z et al. Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF). Cardiovasc Ther 2018:e12478. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390409
  7. Kim YH, Her AY, Jeong MH et al. Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of new-generation drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30474346
  8. Marume K, Takashio S, Nagai T et al. Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease- Report From the JASPER Study. Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30416189
  9. Koskinas KC, Windecker S, Buhayer A et al. Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30421481
  10. Halandras PM. Vascular Surgery and Geriatric Patients. Clinics in geriatric medicine 2019; 35:93-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=30390986
  11. Heeney SA, Tjugum SL, Corkish ME, Hollis IB. Safety and tolerability of high intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus. Clinical transplantation 2018:e13454. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485535
  12. Oshakbayev K, Bimbetov B, Manekenova K et al. Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial. Current medical research and opinion 2018:1-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=30431378
  13. Hansen M, Kuhlman ACB, Sahl RE et al. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30389229
  14. Itoh H, Komuro I, Takeuchi M et al. Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy Study. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393955
  15. Sampalis JS, Psaradellis E, Stutz M et al. Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly. Drugs in R&D 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30448890
  16. Qvist I, Sogaard R, Lindholt JS et al. Adherence to Prescribed Drugs Among 65-74 Year Old Men Diagnosed with Abdominal Aortic Aneurysm or Peripheral Arterial Disease in a Screening Trial: A VIVA Substudy. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30393062
  17. Chen X, Zhuang X, Peng Z et al. Intensive Statin Therapy for Acute Ischemic Stroke to Reduce the Number of Microemboli: A Preliminary, Randomized Controlled Study. European neurology 2018; 80:163-170. http://www.ncbi.nlm.nih.gov/pubmed/?term=30485853
  18. Baik SY, Kim H, Yang SJ et al. Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea. Frontiers of medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30483915
  19. Parisi V, Petraglia L, D'Esposito V et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol 2019; 274:326-330. http://www.ncbi.nlm.nih.gov/pubmed/?term=30454723
  20. Asberg S, Farahmand B, Henriksson KM, Appelros P. Statins as secondary preventives in patients with intracerebral hemorrhage. Int J Stroke 2018:1747493018816476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30484749
  21. Szarek M, White HD, Schwartz GG et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30428396
  22. Bonaca MP, Gutierrez JA, Cannon C et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. The lancet. Diabetes & endocrinology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30396865
  23. Wu NQ, Guo YL, Zhu CG et al. Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018; 17:265. http://www.ncbi.nlm.nih.gov/pubmed/?term=30470229
  24. Ong KL, Hui N, Januszewski AS et al. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30452928
  25. Bhatt DL, Steg PG, Miller M et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415628
  26. Polster SP, Stadnik A, Akers AL et al. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30476251
  27. Kasama S, Toyama T, Suzuki S et al. Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure. Nuclear medicine communications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461696
  28. Liping Z, Xiufang L, Tao Y et al. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci 2018; 31:2203-2208. http://www.ncbi.nlm.nih.gov/pubmed/?term=30463813
  29. Yucel H, Yucel A, Arbag H et al. Effect of Statins on Hearing Function and Subjective Tinnitus in Hyperlipidemic Patients. Romanian journal of internal medicine = Revue roumaine de medecine interne 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30447148

Women and elderly

  1. Ofori-Asenso R, Ilomaki J, Tacey M et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30402916
  2. Lwin EMP, Leggett C, Ritchie U et al. Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations. Drug design, development and therapy 2018; 12:3645-3651. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464396
  3. Guan S, Zhang Y, Wang B, Li W. Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD. Int Heart J 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464115
  4. Ofori-Asenso R, Ilomaki J, Tacey M et al. Predictors of statin use among older adults: A nationwide cross-sectional study. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30446321
  5. Li J, Liu R, Sun Z et al. The association between statin use and endometrial cancer survival outcome: A meta-analysis. Medicine (Baltimore) 2018; 97:e13264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30461633
 
 
 
 
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.